Scarica l'app Stockscreener
11.62
7.04%
-0.88
Dopo l'orario di chiusura:
11.65
0.03
+0.26%
Precedente Chiudi:
$12.50
Aprire:
$12.22
Volume 24 ore:
407.55K
Relative Volume:
1.95
Capitalizzazione di mercato:
$444.11M
Reddito:
$239.40M
Utile/perdita netta:
$104.44M
Rapporto P/E:
3.9257
EPS:
2.96
Flusso di cassa netto:
$-18.50M
1 W Prestazione:
-9.15%
1M Prestazione:
+15.39%
6M Prestazione:
+119.66%
1 anno Prestazione:
+9.83%
Intervallo 1D:
$11.53
$12.41
Intervallo di 1 settimana:
$11.21
$12.93
Portata 52W:
$4.93
$12.93
Entrada Therapeutics Inc Stock (TRDA) Company Profile
Nome
Entrada Therapeutics Inc
Settore
Industria
Telefono
857-305-1825
Indirizzo
ONE DESIGN CENTER PLACE, BOSTON
Compare TRDA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
11.62 | 477.74M | 239.40M | 104.44M | -18.50M | 2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-11 | Iniziato | Guggenheim | Buy |
| 2026-01-28 | Iniziato | Oppenheimer | Outperform |
| 2024-12-06 | Iniziato | ROTH MKM | Buy |
| 2024-01-05 | Iniziato | Oppenheimer | Outperform |
| 2023-04-03 | Iniziato | H.C. Wainwright | Buy |
Entrada Therapeutics Inc Borsa (TRDA) Ultime notizie
HC Wainwright Issues Positive Forecast for TRDA Earnings - MarketBeat
Form 144: TRDA insider sales — Kory Wentworth sold 8,651 shares (TRDA) - Stock Titan
TRDA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Entrada Therapeutics (TRDA) CEO gets RSUs, options and tax-related share sales - Stock Titan
Entrada Therapeutics (TRDA) CFO receives new equity grants and automatic tax share sales - Stock Titan
Entrada Therapeutics (TRDA) COO logs new RSU, option grants and tax share disposals - Stock Titan
Entrada Therapeutics (TRDA) grants RSUs and options as automatic share sales cover taxes - Stock Titan
Advancing Exon-Skipping and Undervalued DM1 Collaboration Underscore Buy Rating on Entrada Therapeutics - TipRanks
Entrada Therapeutics Announces Inducement Grants - National Today
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
Entrada Therapeutics (NASDAQ:TRDA) Stock Rating Upgraded by Wall Street Zen - Defense World
The Technical Signals Behind (TRDA) That Institutions Follow - Stock Traders Daily
Entrada Therapeutics earnings beat by $0.04, revenue fell short of estimates - Investing.com Canada
TRDA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Entrada Therapeutics (NASDAQ:TRDA) Posts Earnings Results, Beats Estimates By $0.38 EPS - MarketBeat
Entrada Therapeutics, Inc. (TRDA) Stock Analysis: Exploring A 54% Potential Upside - DirectorsTalk Interviews
Entrada Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
TRDAForm S-8Securities to be offered to employees in employee benefit plans - ADVFN Ltd
Entrada Therapeutics Q4 net loss and EPS beat expectations - TradingView
Earnings Summary: Entrada Therapeutics Q4 - Benzinga
Entrada Therapeutics, Inc. SEC 10-K Report - TradingView
Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - Bitget
Entrada Therapeutics (NASDAQ: TRDA) maps DMD, DM1 and ocular drug pipeline - Stock Titan
Entrada Therapeutics (TRDA) swings to 2025 loss while advancing DMD pipeline - Stock Titan
DMD trials advance as Entrada extends cash runway to Q3 2027 - Stock Titan
Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (DAWN) and Xenon (XENE) - The Globe and Mail
Duchenne Muscular Dystrophy Clinical Trial Pipeline Gains Momentum: 75+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - StreetInsider
Entrada Therapeutics (TRDA) Soars 5.6%: Is Further Upside Left in the Stock? - MSN
Signal Recap: How does Entrada Therapeutics Inc compare to its peersQuarterly Risk Review & Community Trade Idea Sharing Platform - baoquankhu1.vn
What analysts say about Entrada Therapeutics Inc. stockM&A Rumor & Long-Term Safe Investment Plans - mfd.ru
Entrada Therapeutics’ (TRDA) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Entrada Therapeutics, Inc. (TRDA) Stock Analysis: Potential Upside of 67.57% Could Attract Investors - DirectorsTalk Interviews
Earnings Preview: Entrada Therapeutics, Inc. (TRDA) Q4 Earnings Expected to Decline - Finviz
Entrada Therapeutics (TRDA) to Release Earnings on Thursday - Defense World
EyePoint (EYPT) Surges 15.2%: Is This an Indication of Further Gains? - Yahoo Finance
HC Wainwright & Co. Reiterates Buy Rating on TRDA with $20 PT | - GuruFocus
Market Pulse: Should I trade or invest in Century Therapeutics IncJuly 2025 Big Picture & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study - Bitget
Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study - The Manila Times
Duchenne drug trial doubles dose to 12 mg/kg, aims at accelerated FDA approval - Stock Titan
Entrada Therapeutics Teases Data-Rich 2026 With DMD and DM1 Catalysts at Guggenheim Summit - Defense World
Precision Trading with Entrada Therapeutics Inc. (TRDA) Risk Zones - Stock Traders Daily
What are Entrada Therapeutics Inc.’s recent SEC filings showingLayoff News & AI Driven Stock Price Forecasts - mfd.ru
Why analysts remain bullish on Entrada Therapeutics Inc. stockBear Alert & Reliable Price Breakout Alerts - mfd.ru
Will Entrada Therapeutics Inc. stock gain from lower inflationJuly 2025 Patterns & Long-Term Capital Growth Ideas - mfd.ru
Entrada Therapeutics (NASDAQ:TRDA) Raised to Strong-Buy at Guggenheim - MarketBeat
Published on: 2026-02-13 04:19:34 - mfd.ru
Will Entrada Therapeutics Inc. benefit from rising consumer demandMarket Risk Analysis & High Conviction Buy Zone Alerts - mfd.ru
Can Entrada Therapeutics Inc. outperform under higher oil pricesEarnings Growth Summary & Low Risk Entry Point Tips - mfd.ru
This Olema Pharmaceuticals analyst begins coverage on a bullish note; here are top 4 initiations for Wednesday - MSN
Entrada Therapeutics, Inc. (TRDA) Stock Analysis: Exploring A Bold 67% Upside Potential - DirectorsTalk Interviews
Entrada Therapeutics Inc Azioni (TRDA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.69%
0.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):